

**Supplementary table 3. Management plan for PrEP users with referral eGFR 30-44 (ml/min/1.73m<sup>2</sup>) (n=10)**

Management plan		Total number of unique PrEP users (n)	Outcomes (n)			Follow-up eGFR (by CKD category) at median days of =95days			
			Started/Continued with event-based dosing	Started/Continued with daily dosing	Discontinued/decided not to start	Improved: eGFR increased >59 (ml/min/1.73m <sup>2</sup> )	Improved: eGFR increased 45-59 (ml/min/1.73m <sup>2</sup> )	GFR remained between 30-44 (ml/min/1.73m <sup>2</sup> )	Reduction: eGFR reduced to <30 (ml/min/1.73m <sup>2</sup> )
Trial of event-based dosing and repeat eGFR, given risk/benefit		1	0	0	1	0	0	0	1*
High protein intake/supplements/recreation and normalised	Stop supplements and repeat	3	3	0	0	2	1	0	0
	Stop supplements, switch to event-based dosing and repeat	3	3	0	0	2	1	0	0
Urgent GP/hospital review		1	0	0	1	n/a	n/a	n/a	n/a
Reviewed risk benefit and decided not to start		2	0	0	2	n/a	n/a	n/a	n/a
Footnote									

\*reduced by 3 (ml/min/1.73m<sup>2</sup>) and discontinued